Research Flow Chart Design of Batak Tribe



Research Flow Chart Design of Non-Batak Tribe



Baseline Characteristics

Table 1. The sample distribution based on research subject characteristic

Characteristic	Batak			NonBatak			Batak-Non Batak
	Risperidone + Divalproex Sodium	Risperidone	*p*	Risperidone + Divalproex Sodium	Risperidone	*p*	*p*
Marital Status							
Married							
Single	5(33.333)	5(33.333)	1.000*	5(33.333)	6(40.000)	0.605*	0.347*
	10(66.667)	10(66.667)		10(66.667)	9(60.000)		
Occupation							
Work	5(33.333)	4(26.667)	0.706*	6(40.000)	5(33.333)	0.605**	0.720**
Do not work	10(66.667)	11(73.333)		9(60.000)	10(66.667)		
Education							
SD - SMP	8(53.333)	8(53.333)	1.000*	6(40.000)	6(40.000)	1.000*	1.000*
SMA –Higher Education	7(46.667)	7(46.667)		9(60.000)	9(60.000)		
Age	28.73 (4.56)	29.38 (4.56)	0.640****	30.13(4.76)	31.07(4.87)	0.940****	0.426****
Duration of Illness	5.13 (2.47)	5.38 (2.58)	0.781***	5.03(2,37)	4.58(2.36)	1.481***	0.534***
BMI	22.02 (1.55)	22.70(1.91)	0.144****	22.20(1.65)	22.60(1.81)	0.230****	0.675****
PANSS Positive week 0	32.400 ± 2.444	32.933 ± 2.219	0.573***	31.930 ± 2.434	31.543 ± 2.201	0.457***	0.587***
PANSS Negative Week 0	24.000±3.873	22.667±2.289	0.261***	23.532±3.643	21.964±2.369	0.381***	0.643***
PANSS Total Score week 0	94.400±3.661	93.067±3.195	0.297***	93.700±3.661	92.567±3.605	0.210***	0.857***

**Chi-Square test, **Fisher test, ***Independent t-test, ****Man Whitney u, p<0.05*

Outcome Measures

Table 2. The difference of PANSS positive scale score on Batak and non Batak males with schizophrenia who receive risperidone treatment with sodium divalproex and who receive risperidone monotherapy

PANSS Positive	Batak			Non Batak			Batak-Non Batak
	Risperidone + Sodium Divalproex	Risperidone	*p*	Risperidone + Sodium Divalproex	Risperidone	*p*	*p*
Week 0	32.400 ± 2.444	32.933 ± 2.219	0.000*	31.930 ± 2.434	31.543 ± 2.201	0.000*	0.766
Week 3	21.933± 2.154	25.200±1.014		20.733± 2.138	24.420±1.514		
Week 6	15.400 ±1.352	19.733±1.486		14.820 ±1.355	18.933±1.458		

* *General Linear Model, p<0.05*

Table 3. The difference of PANSS negative scale score on Batak and non Batak males with schizophrenia who receive risperidone treatment with divalproex sodium and who receive risperidone monotherapy

PANSS Negative	Batak			Non Batak			Batak – Non Batak
	Risperidone + Divalproex Sodium	Risperidone	*p*	Risperidone + Divalproex Sodium	Risperidone	*p*	*p*
Week 0	24.000±3.873	22.667±2.289	0.000*	23.532±3.643	21.964±2.369	0.000*	0.789
Week 3	11.600 ±1.502	14.867±1.600		11.350 ±1.502	13.987±1.930		
Week 6	8.867±1.060	12.200±2.932		8.867±1.060	12.200±2.932		

* *General Linear Model, p<0.05*

Table 4. The difference of PANSS total score on Batak and non Batak males with schizophrenia who receive risperidone treatment with divalproex sodium and who receive risperidone monotherapy

PANSS Total Score	Batak			Non Batak			Batak –Non Batak
	Risperidone + Divalproex Sodium	Risperidone	*p*	Risperidone + Divalproex Sodium	Risperidone	*p*	*p*
Week 0	94.400±3.661	93.067±3.195	0.000*	93.700±3.661	92.567±3.605	0.000*	0.673
Week 3	60.000 ±2.330	69.267±1.335		59.800 ±2.070	68.674±1.935		
Week 6	46.067±2.404	55.200±1.740		45.201±2.186	54.600±1.156		

* *General Linear Model, p<0.05*

Adverse Events

Table 5. Frequency of the adverse effects for both study groups

Advers Effect	Batak			Non Batak		
	Risperidone-Divalproex Sodium	Risperidone	*p*	Risperidone-Divalproex Sodium	Risperidone	*p*
Weight gain	3	2	1.000	2	1	1.000
liver function enhancement	1	1	1.000	2	1	1.000
Gastrointestinal Effect	5	2		5	3	0.660
Extrapyramidal Syndrome	2	1	0.400	1	1	1.000
(Tremor)			1.000			

Fisher test $p<0.05$